Foreign fund house Sloane Robinson LLP has raised its stake to 5.31 per cent in Glenmark Pharmaceuticals Ltd through an open market transaction.
The fund house has acquired over 8.47 lakh equity shares, representing 0.34 per cent stake, for an undisclosed amount, Glenmark Pharmaceuticals said in a filing with the Bombay Stock Exchange.
The fund house purchased equity shares on July 3. Based on the closing price of Rs 236.20 on BSE that day, the deal values at approximately Rs 20 crore.
The foreign fund house had 4.97 per cent stake in the company before the latest acquisition.
Sloane Robinson LLP bought these shares for eight overseas-based funds while acting as an investment manager.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app